Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.

A phase 1-2 trial of 90Y-labelled monoclonal antibody, HMFG1 administered intraperitoneally to 30 patients with ovarian carcinoma is presented. The problems encountered with myelotoxicity are described, and the steps which have so far been taken to overcome this and to increase the dose of 90Y to an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hird, V., Stewart, J. S., Snook, D., Dhokia, B., Coulter, C., Lambert, H. E., Mason, W. P., Soutter, W. P., Epenetos, A. A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 1990
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2149520/
https://ncbi.nlm.nih.gov/pubmed/2383480
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi